C4 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule protein degraders using its proprietary TORPEDO platform to harness the body's natural protein destruction processes for treating cancer and neurological diseases. The company's lead program, cemsidomide, is in Phase 2 development for multiple myeloma, while CFT8919 targets mutant EGFR in non-small-cell lung cancer with additional discovery-stage programs in inflammation and neurodegeneration. C4 generates revenue through partnership agreements with pharmaceutical companies including Merck KGaA, Roche, Biogen, and Betta Pharma, receiving upfront payments and milestone-based royalties, and plans to establish its own US sales organization and pursue partnerships for commercialization upon regulatory approval of its lead candidates.